STRONG EXPANSION AT KNOLL IN 1991

12 April 1992

The drug-making arm of the German chemical concern BASF, Knoll AG, has reported a 9% expansion of sales worldwide in 1991 to 2.2 billion Deutschemarks ($1.3 billion), compared with a rise of 8.5% in 1990.

In Germany, group sales increased 6% to 1.1 billion marks, while those of the parent company went up 4.3% to 889 million marks. Drugs and active principles made up 84% of world sales amounting to 1.8 billion marks, a rise of 10.4%.

Sales of infusion solutions, dialysis products and medical-technical products, recently sold to Fresenius (Marketletter March 23), went up 10.2% to 183 million marks. Pharmaceutical chemicals sales grew 3.4%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight